– USA, TN – Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced the appointment of Dr. Vlad Coric (M.D.) to its Board of Directors, effective March 1, 2023, bringing more than 22 years of drug development and executive leadership experience based on his time at the Yale School of Medicine, Bristol-Myers Squibb, and Biohaven.
“Vlad’s leadership and proven track record in biotech value creation from discovery to commercialization, particularly in the field of neurology, will further enhance the collective experience and skillset of our diverse Board. His appointment comes at a dynamic time for Revance as we accelerate our commercial growth in aesthetics and look to advance our significant opportunity in therapeutics,” said CEO, Mark Foley.
The company also announced that Philip Vickers will be retiring from the Board effective immediately prior to the 2023 AGM.
About Dr. Vlad Coric
Dr. Vlad Coric is currently the Chairman and CEO of Biohaven, where he has successfully led the approval and commercialization of its Nurtec ODT and CGRP franchise in addition to the expansion of the company’s therapeutic portfolio targeting neurological and neuropsychiatric diseases. He also led Biohaven’s acquisition of its novel Kv7 channel platform and the sale of Biohaven to Pfizer in October 2022 for total consideration of $13 billion. Previously, Dr. Coric was the Group Director of Neuroscience and Oncology Global Clinical Research, and Medical Director, of Neuroscience Global Clinical Research, at Bristol-Myers Squibb Company. He also previously served on the board of directors of Social Capital Suvretta Holdings Corp. I from 2021-2022 and he currently serves on the boards of directors of private biotech companies including Veradermics, Inc., Vita Therapeutics, Inc., and Pyramid Biosciences, Inc.
During his career, Dr. Coric has been involved in multiple drug development programs, including marketed drugs or filed NDAs such as Nurtec ODT, zavegepant, Abilify, Opdivo, Yervoy, Daklinza, and Sunvepra.
“Revance’s people, strategy and breakthrough innovation in the neuromodulator category uniquely positions the company to disrupt both the aesthetics and therapeutics market,” said Dr. Valid Coric. “I look forward to working with Mark, the rest of the leadership team, and the Board to support Revance’s continued progress and advancement of innovative therapies that have the potential to maximize the benefit of DAXXIFY’s efficacy and long-duration profile.”
Dr. Coric is an Associate Clinical Professor of Psychiatry at the Yale School of Medicine, has published over 65 peer-reviewed publications, and has lectured nationally on neurological and psychiatric disorders. He earned his medical degree from Wake Forest University School of Medicine and was an honors scholar in neurobiology and physiology at the University of Connecticut, where he received his Bachelor of Science degree.
About Revance
Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that elevate patient and physician experiences. Revance’s aesthetics portfolio of expertly created products and services, including DAXXIFY for injection, the RHA Collection of dermal fillers, and OPUL, the first-of-its-kind Relational Commerce platform for aesthetic practices, deliver a differentiated and exclusive offering for the company’s elite practice partners and their consumers. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection, which will compete in the existing short-acting neuromodulator marketplace. Revance’s therapeutics pipeline is currently focused on muscle movement disorders including evaluating DAXXIFY in two debilitating conditions, cervical dystonia, and upper limb spasticity.
Revance is headquartered in Nashville, Tennessee, with additional office locations in Newark, Pleasanton, and Irvine, California.
For more information : https://www.revance.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
